San Diego, CA -- (SBWIRE) -- 05/10/2017 -- An investor, who purchased NYSEMKT:TXMD shares , filed a lawsuit against TherapeuticsMD Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.

Investors who purchased shares of TherapeuticsMD Inc (NYSEMKT:TXMD) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint the plaintiff alleges on behalf of purchasers of TherapeuticsMD Inc (NYSEMKT:TXMD) common shares between July 7, 2016 and April 9, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 7, 2016 and April 9, 2017, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: the Company's New Drug Application (NDA) submission for TX-004HR was deficient, that the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient, and that the deficient NDA would likely cause a delay of the FDA's potential approval of the TX-0004HR NDA.

On April 10, 2017, TherapeuticsMD Inc announced receipt of a letter from the U.S. Food and Drug Administration ("FDA"stating that its ongoing review of the Company's New Drug Application (NDA) for TX-004HR has discovered "deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Those who purchased shares of TherapeuticsMD Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com